Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for crohn's disease

American Journal of Gastroenterology

Volumn 104, Issue 8, 2009, Pages 1976-1983

  Feagan, Brian G ^a   Coteur, Geoffroy ^b   Tan, Seng ^c   Keininger, Dorothy L ^b   Schreiber, Stefan ^d  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UCB PHARMA   (Belgium)

^c Global Health Outcomes Research   (United Kingdom)

^d UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOLIZUMAB PEGOL; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; HEALTH SURVEY; HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36;

ADULT; CROHN DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; POLYETHYLENE GLYCOLS; QUALITY OF LIFE;

EID: 68349135452     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.199     Document Type: Article

References (33)

1. Cohen RD. The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther 2002;16:1603-9.
2. Casellas F, Lopez-Vivancos J, Vergara M et al. Impact of inflammatory bowel disease on health-related quality of life. Dig Dis 1999;17:208-18.
3. Irvine EJ, Feagan B, Rochon J et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994;106:287-96.
4. Drossman DA, Patrick DL, Mitchell CM et al. Health-related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns. Dig Dis Sci 1989;34:1379-86.
5. Feagan BG, Bala M, Yan S et al. Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol 2005;39:390-5.
6. Best WR, Becktel JM, Singleton JW et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterol 1976;70:439-44.
7. Bernklev T, Jahnsen J, Aadland E et al. Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis. Scand J Gastroenterol 2004;39:365-73.
8. Guyatt G, Mitchell A, Irvine EJ et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804-10.
9. Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006;4:79.
10. Irvine EJ. Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1999;28: S23-7.
11. Bernklev T, Jahnsen J, Lygren I et al. Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis 2005;11:909-18.
12. Juan J, Estiarte R, Colome E et al. Burden of illness of Crohn's disease in Spain. Dig Liver Dis 2003;35:853-61.
13. Welch G, Richter J, Kawachi I et al. The SF-36 quality of life measure in inflammatory bowel disease: an evaluation of its reliability and validity. Gastroenterology 1995;108: A940.
14. König HH, Ulshofer A, Gregor M et al. Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002;14:1205-15.
15. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-65.
16. Feagan BG, Yan S, Bala M et al. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003;98:2232-8.
17. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
18. Feagan BG, Enns R, Colombel JF et al. Maintenance natalizumab results in greater quality of life in Crohn's disease patients. Gut 2005;54: A18-9.
19. Ghosh S, Allison M, Nwokolo C et al. Maintenance therapy with natalizumab improves quality of life in patients with Crohn's disease. Gut 2005;54: A23.
20. Fossati G, Nesbitt AM. In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870) [abstract]. Am J Gastroenterol 2005;100: S299.
21. Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38.
22. Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50.
23. Ware JE Jr. SF-36 health survey update. Spine 2000;25:3130-9.
24. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-43.
25. Reilly MC, Gerlier L, Brown M. Discriminant validity of the work productivity and activity impairment questionnaire in patients with Crohn's disease [abstract]. Value Health 2006;9: A246-7.
26. Keininger DL, Feagan BG, Coteur G et al. Interpretation of SF-36 score changes in active Crohn's disease (CD) patients. Gastroenterol 2007;132: A-475.
27. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108.
28. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005;43:203-20.
29. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
30. Schreiber S, Rutgeerts P, Fedorak RN et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129:807-18.
31. Kulig M, Leodolter A, Vieth M et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease - an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003;18:767-76.
32. Lackner JM, Gudleski GD, Zack MM et al. Measuring health-related quality of life in patients with irritable bowel syndrome: can less be more? Psychosom Med 2006;68:312-20.
33. Siegel CA, Hur C, Korzenik JR et al. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1017-24.